Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies

• Published in: mAbs 2015-01, Vol.7 (1), p.192-198
• Main Authors: Duong, Minh Ngoc, Matera, Eva-Laure, Mathé, Doriane, Evesque, Anne, Valsesia-Wittmann, Sandrine, Clémenceau, Béatrice, Dumontet, Charles
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - pharmacology; Antibodies, Neoplasm - pharmacology; Antibody-Dependent Cell Cytotoxicity - drug effects; Antibody-Dependent Cell Cytotoxicity - immunology; Cancer; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors - pharmacology; Humans; Life Sciences; Mice; Mice, SCID; Neutrophils - immunology; Phagocytosis - drug effects; Phagocytosis - immunology
• ISSN: 1942-0862; 1942-0870
• DOI: 10.4161/19420862.2015.989020

Targeted therapies of malignancies currently consist of therapeutic monoclonal antibodies and small molecule kinase inhibitors. The combination of these novel agents raises the issue of potential antagonisms. We evaluated the potential effect of 4 kinase inhibitors, including the Bruton tyrosine kinase inhibitor ibrutinib, and 3 PI3K inhibitors idelalisib, NVP-BEZ235 and LY294002, on the effects of the 3 monoclonal antibodies, rituximab and obinutuzumab (directed against CD20) and trastuzumab (directed against HER2). We found that ibrutinib potently inhibits antibody-dependent cell-mediated cytotoxicity exerted by all antibodies, with a 50% inhibitory concentration of 0.2 microM for trastuzumab, 0.5 microM for rituximab and 2 microM for obinutuzumab, suggesting a lesser effect in combination with obinutuzumab than with rituximab. The 4 kinase inhibitors were found to inhibit phagocytosis by fresh human neutrophils, as well as antibody-dependent cellular phagocytosis induced by the 3 antibodies. Conversely co-administration of ibrutinib with rituximab, obinutuzumab or trastuzumab did not demonstrate any inhibitory effect of ibrutinib in vivo in murine xenograft models. In conclusion, some kinase inhibitors, in particular, ibrutinib, are likely to exert inhibitory effects on innate immune cells. However, these effects do not compromise the antitumor activity of monoclonal antibodies in vivo in the models that were evaluated.